The rapid onset of massive, systemic viral replication during primary HIV or simian immunodeficiency virus (SIV) infection and the immune evasion capabilities of these viruses pose fundamental problems for vaccines that depend upon initial viral replication to stimulate effector T cell expansion and differentiation [1] [2] [3] [4] [5] . We hypothesized that vaccines designed to maintain differentiated effector memory T cell (T EM cell) responses 5, 6 at viral entry sites might improve efficacy by impairing viral replication at its earliest stage 2 , and we have therefore developed SIV protein-encoding vectors based on rhesus cytomegalovirus (RhCMV), the prototypical inducer of life-long T EM cell responses [7] [8] [9] . RhCMV vectors expressing SIV Gag, Rev-Tat-Nef and Env persistently infected rhesus macaques, regardless of preexisting RhCMV immunity, and primed and maintained robust, SIV-specific CD4 + and CD8 + T EM cell responses (characterized by coordinate tumor necrosis factor, interferon-c and macrophage inflammatory protein-1b expression, cytotoxic degranulation and accumulation at extralymphoid sites) in the absence of neutralizing antibodies. Compared to control rhesus macaques, these vaccinated rhesus macaques showed increased resistance to acquisition of progressive SIVmac239 infection upon repeated limiting-dose intrarectal challenge, including four macaques who controlled rectal mucosal infection without progressive systemic dissemination. These data suggest a new paradigm for AIDS vaccine development-vaccines capable of generating and maintaining HIV-specific T EM cells might decrease the incidence of HIV acquisition after sexual exposure.
According to current concepts of T cell-directed HIV vaccines 3, 4, 10 , a broadly targeted, high-frequency, HIV-specific CD8 + memory T cell response would restrict acute-phase HIV replication and decrease the subsequent chronic-phase HIV replication set point. CD8 + T cell vaccines are not expected to completely prevent or eliminate infection. Rather, by lowering viral load set points, these vaccines would ameliorate the AIDS epidemic by substantially reducing both the rate of disease progression in infected individuals and the likelihood that such individuals would transmit the infection to others. Although experiments in monkey models have supported these principles [11] [12] [13] [14] , the recent STEP phase 2b clinical trial of adenovirus-5 (Ad5) vectors, widely viewed as a test of the CD8 + T cell vaccine concept, was a clear failure, causing many to question the ability of T cell responses to contribute to an effective HIV/AIDS vaccine 3, 10 .
In assessing the lack of efficacy seen in the STEP trial, it is instructive to consider whether the characteristics of the T cell responses elicited by current vaccine strategies are well matched to the goal of lentiviral containment. One key consideration is the influence of differentiation state on the efficacy of vaccine-generated memory T cells. Most current T cell vaccine strategies use nonpersistent vectors that produce antigen for a limited time, and, as the antigen provided by these vectors wanes, the memory T cell responses they elicited become increasingly secondary lymphoid tissue-based, or central memory T cell (T CM cell) in character 5 . T CM cells have limited immediate effector function and require antigen-induced expansion, differentiation and migration to produce peak effector responses at viral replication sites 5, 6 . T CM cell-derived effector responses are accelerated over primary responses but still seem to develop too slowly to prevent the initial systemic dissemination and extensive early replication of SIV in nonhuman primate models 11, 12 . In contrast, agents or vectors that provide a controlled, persistent level of antigen maintain functionally differentiated T EM cells in extralymphoid sites 5, 15, 16 . Given that T EM cells are the predominant type of T cell in mucosal effector sites 8, 17 , and that mucosal HIV transmission is associated with small seed populations of limited genetic diversity 18 , we hypothesized that a vaccine capable of generating and maintaining a potent HIV-specific T EM -type response might improve efficacy by initiating adaptive antiviral immunity at the outset of mucosal infection (the initial 24-48 h), when the virus is probably most susceptible to immune control.
Primate CMVs comprise a family of closely related, but speciesspecific, b-herpes viruses that are ubiquitous, persistent and, for competent immune systems, largely benign [19] [20] [21] . CMV infections are associated with lifelong, high-frequency and highly T EM -biased CD4 + and CD8 + T cell responses that protect against disease development but do not eliminate the CMV infection or prevent CMV superinfection [7] [8] [9] 20, [22] [23] [24] [25] . Therefore, we explored the possibility that RhCMV could be exploited as a persistent vaccine vector for generation of durable SIVspecific, T EM -biased CD4 + and CD8 + T cell responses in rhesus macaques, thereby allowing assessment of the ability of these responses to prevent or completely contain SIV infection during repeated limiting-dose intrarectal challenge. RhCMV-SIV vectors encoding SIV Gag, a Rev-Tat-Nef fusion protein, and Env (Fig. 1a) were constructed and shown to express high amounts of these SIV antigens during lytic infection in vitro and to possess wild-type RhCMV growth kinetics ( Supplementary Figs. 1-3 online) . Administration of RhCMV-SIV vectors to either RhCMV-naive or RhCMV + rhesus macaques resulted in clinically benign primary infection and superinfection, respectively. Virological analysis showed the appearance of RhCMV-SIV vectors in urine and saliva by day 56 after inoculation ( Fig. 1b) , but little to no measurable viremia (data not shown). The persistence of these infections and the genetic stability of the three RhCMV-SIV vectors in vivo were indicated by our ability to culture SIV antigen-expressing RhCMV from urine and saliva co-cultures for up to 664 d after inoculation (Fig. 1b) . Notably, despite the presence of potentially competing RhCMVderived T cell epitopes and the preexisting, high-frequency T cell responses to these epitopes in RhCMV + rhesus macaques, all rhesus macaques inoculated with these RhCMV-SIV vectors developed both CD4 + and CD8 + T cell responses to the recombinant SIV protein(s) (Fig. 1c) . These responses remained detectable for more than 3 years after vector administration (details below and data not shown), suggesting that the RhCMV-vectored, SIVspecific responses persist indefinitely, similar to native RhCMV-specific T cell responses. In contrast to these robust SIV-specific T cell responses, RhCMV-SIV vectors elicited only low-titer antibodies to SIV (detectable at r1:10 dilution of plasma) that were unable to neutralize either SIVmac239 or a highly neutralization-sensitive, tissue culture-adapted variant of SIVmac251 (data not shown).
We next studied the differentiation and functional characteristics of established SIV-specific memory T cells induced by RhCMV-SIV vector vaccination. The markers CD28 and CCR7 define the T CM to T EM cell differentiation axis among rhesus macaque T cells, with T CM , transitional T EM1 and fully differentiated T EM2 cells expressing CD28 + CCR7 + , CD28 + CCR7 À and CD28 À CCR7 À phenotypes, respectively 8, 17 . Both RhCMV-specific and RhCMV-vectored, SIV-specific T cells in peripheral blood showed a nearly exclusive (490%) T EM phenotype, with CD8 + T cells having an almost entirely T EM2 phenotype and CD4 + T cells being about equally split between T EM1 and T EM2 phenotypes (Fig. 2a,b and Supplementary Fig. 4 online) . In sharp contrast, a protein prime-Ad5 boost vaccine induced a predominantly T CM phenotype among SIV-specific CD4 + and CD8 + T cells (P o 0.0001; Fig. 2a and Supplementary Fig. 4 ). In keeping with T EM localization in extralymphoid sites 8, 17 , both RhCMV-specific and RhCMV-vectored, SIV-specific T cells were highly enriched among bronchoalveolar lavage (BAL) lymphocytes (Fig. 2c,d ). Finally, RhCMV-specific and RhCMV-vectored, SIV-specific T cells showed essentially identical functional potential ( Fig. 3 and Supplementary  Fig. 5 online). Specifically, CD4 + T cells were predominantly polyfunctional, capable of simultaneous production of tumor necrosis factor (TNF), interferon-g (IFN-g), interleukin-2 (IL-2) and macrophage inflammatory protein-1b (MIP-1b), the latter being a CCR5-binding chemokine capable of blocking HIV and SIV infection 26 . CD8 + T cells were also capable of producing TNF, IFN-g and MIP-1b, but, consistent with a highly polarized T EM2 phenotype, lacked substantial IL-2 production. The polarized T EM2 phenotype of the RhCMV-vectored, SIV-specific CD8 + T cells would predict cytotoxic potential 6 , and, accordingly, these cells efficiently extruded cytotoxic granules (externalized CD107) upon antigen recognition (Fig. 3c) .
These results indicate that the RhCMV-SIV vectors elicit and maintain SIV-specific T cells that are highly skewed toward T EM differentiation. To test whether this T EM -skewed anti-SIV T cell response would protect against SIV infection, we assembled a cohort 
of 12 long-term RhCMV-SIV vector-vaccinated rhesus macaques (which we used 4486 d from their last RhCMV-SIV vaccination) and 16 unvaccinated wild-type RhCMV + control rhesus macaques for repeated limiting-dose intrarectal challenge with the highly pathogenic SIVmac239 (Fig. 4a) . At the time of challenge, the CMV-SIV Combined boost (6) No boost ( responses, respectively (Fig. 4b) . All 16 control rhesus macaques showed progressive infection over the course of challenge, with 50% of these macaques becoming infected with the first or second dose of virus and the last control macaque infected with the twelfth dose (Fig. 4c) . In contrast, the median number of doses to achieve progressive, systemic infection was eight for the vaccinated group (Fig. 4c) . Most notably, four of the twelve vaccinees failed to show progressive infection (P ¼ 0.024). Two of these four rhesus macaques showed transient plasma virus levels of 60-80 SIV RNA copy equivalents per ml after the first challenge, whereas the other two underwent 13 SIVmac239 challenges without measurable plasma virus (Fig. 4c) . All four rhesus macaques, however, seemed to be infected with SIVmac239 on the basis of their development of reproducible de novo CD8 + T cell responses to two SIV proteins, Pol and Vif, that were not included in the vaccine (Fig. 4d) . Such new SIV-specific T cell responses did not develop in naive rhesus macaques repeatedly challenged with equivalent doses of aldrithiol-2-inactivated SIVmac239 or in three unvaccinated control macaques that were not overtly infected in the six initial challenges with competent SIVmac239 ( Supplementary Fig. 6 online). These controls argue against the possibility that the de novo CD8 + T cell responses to Pol and Vif in the four protected rhesus macaques were related to crosspresentation of SIV proteins in the challenge virus preparation in the absence of infection and, in agreement with previous work 27 , indicate that the typical outcome of repeated limiting-dose intrarectal SIV challenge of unvaccinated rhesus macaques is either no infection or overt progressive infection, with no immune sensitization in the absence of overt infection. At 19 weeks after the first challenge, the four protected rhesus macaques were depleted of CD8 + cells by administration of monoclonal antibody cM-T807, a treatment capable of transiently reversing CD8 + T cell-mediated control of SIV replication 28 . This treatment caused profound depletion of circulating CD8 + T cells but did not result in measurable viremia (Fig. 4c) . Moreover, cell-associated SIV DNA or RNA was not detected by sensitive PCR assays in isolated peripheral blood and lymph node CD4 + T cells from these four rhesus macaques, both before and during maximal CD8 + cell depletion (data not shown). Thus, four of twelve RhCMV-SIV vector-vaccinated rhesus macaques were infected with SIVmac239 via a mucosal route but showed no systemic evidence of infection months later, strongly suggesting that infection was effectively contained locally, before dissemination and establishment of typical systemic infection. This study did not directly compare the efficacy of RhCMV-SIV vectors to other vaccine regimens that induce T CM -biased responses, but it should be noted that the degree of protection observed in this study was not achieved in a test of a potent DNA prime-Ad5 boost vaccine regimen that used the same challenge virus and limiting-dose intrarectal challenge procedure 12 . Our data also do not directly demonstrate the mechanism of this protection, but among the possibilities-T cell, antibody or innate immunity-the most likely candidate is certainly the robust, SIV-specific T EM responses observed in the vaccinees. SIVspecific antibody responses were weak with no neutralization activity, and both vaccinated and control monkeys were chronically infected with RhCMV and 4486 d removed from any overt RhCMV exposure, making it highly unlikely that innate immune activation contributed to protection (although it should be noted that the control rhesus macaques were not experimentally re-infected with RhCMV via vector administration as were the vaccinated macaques).
The presence of class I major histocompatibility variants such as Mamu-B*08 and Mamu-B*17, previously associated with spontaneous, CD8 + T cell-mediated control of viral replication in the chronic phase of SIV infection 4 , did not correlate with the acute phase protective effects we observed (only one of four protected versus five of eight unprotected rhesus macaques were B*17 + or B*08 + ), suggesting potential differences in the mechanism(s) mediating early and local versus late and systemic protection. We speculate that in the four early-protected rhesus macaques reported here, RhCMV vectorgenerated, SIV-specific T EM cells in rectal lamina propria responded to challenge by creating adverse local conditions for viral replication and spread, effectively lowering the basic reproductive ratio of the infection below that required for sustained infection (o1) 2, 29 . In the eight nonprotected rhesus macaques, the local T EM cell responses may have been insufficient to suppress the reproductive ratio to o1, perhaps owing to intrinsic genetic differences among these rhesus macaques or to stochastic variation in local T EM cell distribution and function. In future studies, it will clearly be necessary to quantify the distribution and function of SIV-specific T EM cells in the rectal mucosa so as to define precise correlates of local protection. Not surprisingly, given the extralymphoid localization and relatively low expansion potential of T EM cells, the RhCMV-vectored, SIV-specific T EM cell responses were unable to provide substantial protection once progressive, systemic infection was initiated ( Supplementary Fig. 7 online) . However, it should also be noted that the vaccine-generated, SIV-specific CD4 + CCR5 + T EM cells did not accelerate or enhance viral replication in these 'break-through' infections.
Consistent with our original hypothesis, these results suggest that T EM -biased T cell immunity, in the absence of neutralizing antibody, can prevent establishment of progressive systemic infection after mucosal challenge with a highly pathogenic SIV, presumably by interfering with viral replication at its earliest stages. CMV-based vectors offer one strategy to generate such a T EM cell component, but other strategies that provide persistent, low-level antigen expression could also be explored. It may also be possible to engineer HIV/ AIDS vaccines that generate and maintain both T EM and T CM cell components, the latter serving as a second line of defense if the initial T EM cell barrier is breached. Such T EM cell or combination T EM -T CM cell vaccines will probably not provide absolute protection against all HIV exposure (against parenteral routes, for example). However, our data suggest that vaccine-generated T cell responses are able to do more than simply lower viral replication set points. Specifically, HIV/ AIDS vaccines with a T EM component may have the ability to protect against the sexual transmission of HIV.
METHODS
Rhesus macaques. We used 49 purpose-bred juvenile and adult male rhesus macaques (Macaca mulatta) of Indian genetic background in this study, including 12 RhCMV + and six RhCMV À rhesus macaques inoculated with RhCMV-SIV vectors, nine rhesus macaques that received a Gag protein prime followed by an Ad5(Gag) boost vaccine protocol and 22 RhCMV + rhesus macaques used as unvaccinated controls. All rhesus macaques were free of cercopithicine herpesvirus 1, D-type simian retrovirus, simian Tlymphotrophic virus type 1 and SIV infection at the start of the study, and they were used with approval of the Oregon National Primate Research Center Animal Care and Use Committee, under the standards of the US National Institutes of Health Guide for the Care and Use of Laboratory Animals. We administered RhCMV-SIV vectors subcutaneously at a dose of 1 Â 10 7 plaque-forming units. The Gag protein prime-Ad5(gag) boost protocol consisted of 450 mg SIV Gag protein (Protein Sciences) emulsified in montanide ISA-51 carrier (SEPPIC), with or without 1 mg of polyI:C (Invitrogen), 3M-12 (3M Pharmaceuticals) or class C CpG (Pfizer) adjuvant at weeks 0 and 10, followed by Ad5(gag) (1 Â 10 10 particles, from National Institutes of Health Vaccine Research Center) at week 20. We performed SIVmac239 challenge by administering 300 focus-forming units of virus
weekly via the intrarectal route for the first eight challenges and then, if necessary, five additional weekly challenges at 1,000 focus-forming units. We challenged all of the vaccinated macaques and 12 of the control macaques concurrently, and we challenged the remaining four control rhesus macaques as part of a titration performed immediately before the primary challenge, using the same viral dose and challenge procedure. We followed plasma viral loads weekly, with challenge being discontinued the week after detection of 430 copy equivalents per ml of SIV Gag RNA. For CD8 + cell depletion, we treated rhesus macaques with 10, 5, 5 and 5 mg per kg body weight of the humanized monoclonal antibody cM-T807 (ref. 30 ) on days 1, 3, 5 and 10, respectively. We collected BAL cells as previously described 7 .
Viruses and vectors. We prepared RhCMV constructs expressing SIV proteins (designated RhCMV-SIV viruses; Fig. 1a ) with a bacterial artificial chromosome (BAC) containing the entire RhCMV strain 68-1 genome (pRhCMV-BAC-Cre), as previously described 31, 32 (see Supplementary  Fig. 1 ). We confirmed the genomic integrity of the recombinant RhCMV-SIV BACs by restriction enzyme digestion, Southern analysis and direct DNA sequence analysis of the SIV open reading frames (data not shown). We reconstituted RhCMV-SIV viruses by transfection of BAC DNA into RhCMV-permissive rhesus fibroblasts and confirmed expression of SIV antigens by western blot analysis of RhCMV-SIV-infected cell lysates (Supplementary Fig. 2 ). Multistep growth analysis of RhCMV-SIV viruses 31 showed growth kinetics comparable to wild-type RhCMV ( Supplementary Fig. 3 ). The pathogenic SIV challenge stock (kindly provided by C.J. Miller) was generated by expanding the SIVmac239 clone 33 in rhesus macaque peripheral blood mononuclear cells and quantified by sMAGI cell assay 34 and quantitative RT-PCR for SIV genomic RNA 35 . We prepared AT-2-inactivated SIVmac239 (lot P4146) as previously described 36 and normalized this stock to the infectious SIVmac239 stock by real-time RT-PCR quantification of SIV genome copy number.
Viral detection assays. We centrifuged filter-sterilized (0.4 mm) urine at 16,000g for 1 h at 4 1C to concentrate virus for co-culture on rhesus fibroblasts. After we observed extensive cytopathic effects, or after 42 d of coculture if cytopathic effects were minimal or not observed, we prepared cell lysates and assessed RhCMV-SIV vector replication on the basis of expression of SIV antigen-specific epitope tags by western immunoblotting. We measured whole-blood RhCMV DNA, plasma SIV RNA, and cell-associated SIV DNA and RNA by real-time PCR and RT-PCR assays 24, 35, 37 , with the cell-associated SIV quantification with immunobead-isolated CD4 + T cells before and after a 48-h stimulation with an immobilized antibody to CD3 and recombinant IL-2 and including RT-PCR analysis of supernatants of the stimulated cells.
Immunologic assays. We measured RhCMV-and SIV-specific CD4 + and CD8 + T cell responses by flow cytometric intracellular cytokine analysis (FCICA) of peripheral blood mononuclear cells and BAL cells, as previously described 7, 24, 25, 38 (see Supplementary Methods online). We measured antibody binding to SIV by ELISA of purified SIVmac239 viral lysates 39 . We measured neutralizing antibodies against SIVmac239 and tissue cultureadapted SIVmac251 in luciferase reporter gene assays with the TZM-bl and M7 Luc cell lines, respectively 40 .
Statistical analyses. We performed statistical analyses with SAS version 9.1 (Statistical Analysis System). We assessed the significance of differences in the phenotype or functional properties of RhCMV-specific T cells versus RhCMVvectored, SIV-specific T cells versus prime-boost-elicited SIV-specific T cells by mixed-effects analysis; the proportion of rhesus macaques within the vaccinated versus control groups that completely controlled SIV infection after repeated, limiting-dose mucosal challenge by a two-sided Fischer's exact test; and the peak and mean plateau phase (day 42 to day 91) plasma viral loads of the control versus vaccinated rhesus macaques with progressive infection by general linear models with log 10 -transformed data. In all analyses, we used a two-sided significance level of 0.05, with correction made for multiple comparisons using the Bonferroni method.
Note: Supplementary information is available on the Nature Medicine website. Retanef(int) is a fusion of simian immunodeficiency virus (SIV) rev (Met1-Leu19), int (Lys159-Ala293), full-length nef (starting at Ala4) and tat (Glu2-Arg82), mutagenized to decrease toxicity, essentially as previously described by Kulkarni et al. (Vaccine 29, 6742-6754, 2011) . Table 1 shows a comparison between Retanef(Hel) (Vaccine 20, 3171-3186, 2002) and our Retanef(int) construct.
In Figure 4d of our paper, the appearance of de novo CD8 + T cell responses to overlapping peptides comprising the full-length SIV pol protein in the four stringently protected RhCMV-SIV-vaccinated rhesus macaques after SIVmac239 challenge was used as evidence of occult SIV infection. Although the presence of a pol component-int(Lys159-Ala293)-within the RhCMV-Retanef(int) vector would bring this conclusion into question, several lines of evidence strongly support our original interpretation. First, as we initially indicated, two of the four protected rhesus macaques showed transient SIV viremia, and all four of these rhesus macaques showed the appearance of de novo CD8 + responses to peptides comprising full-length SIV vif (a protein not included in the vaccine). Second, peripheral blood mononuclear cells from a total of 23 RhCMV-Retanef(int)-vaccinated and three SIV-infected rhesus macaques were found to be negative for both CD4 + and CD8 + T cell responses to peptide mixes comprising int (Lys159-Ala293), indicating this region is poorly immunogenic or nonimmunogenic for T cells in rhesus macaques. Finally, further analysis of cryopreserved T cells from the four protected monkeys in our study specifically shows the absence of CD8 + T cell responses to full-length pol, int(Lys159-Ala293) and the SIV rev/tat regions unique to the retanef(Hel) construct (and not in the RhCMV-retanef(int) vector administered to these rhesus macaques) prior to SIVmac239 challenge, as well as the appearance of such responses to full-length pol and the unique retanef(Hel) regions, but not the int(Lys159-Ala293), in all monkeys after SIV challenge (Fig. 1) . Thus, challenge was associated with the induction of de novo CD8 + T cell responses to multiple distinct SIV sequences that were not included in the vaccine (that is, full-length vif, pol other than int(Lys159-Ala293), rev(Leu20-Asp100) and tat(Arg83-Arg131)), consistent, as we originally suggested, with controlled SIV infection. Thus, none of the conclusions of our original report are affected by the use of RhCMV-Retanef(int) reported in this addendum. Figure 1 Immunogenicity profiles of RhCMV-retanef(int)-vaccinated controllers before and after SIV challenge. Flow cytometric intracellular cytokine analysis (FCICA) (Nat. Med. 15, 293-299, 2009) of peripheralblood CD8 + T cells responding to 15-mer overlapping peptides comprising amino acid sequences common or unique to Retanef(Hel) and Retanef(int) in the four RhCMV-retanef(int)-vaccinated, SIV controllers we initially reported before and after SIV challenge. The percentage of responding SIV antigen-specific CD8 + T cells (producing tumor necrosis factor-α, interferon-γ or both) within the overall memory subset is shown. Responses before challenge were restricted to sequences included in the RhCMVretanef(int) vector, whereas after challenge responses to sequences that are only expressed by the SIV challenge virus are identified. The only exception to this pattern is the int(Lys159-Ala293) sequence, which, though included in the RhCMV-retanef(int) vector and in SIV itself, is nonimmunogenic for T cells both before and after challenge.
